Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice.
Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Research Abstract Details
Leflunomide is an immunosuppressive agent that inhibits de novo synthesis of pyrimidine nucleotides and the activity of protein tyrosine kinase. This study examined the teratogenicity of Leflunomide in mice. Pregnant mice were treated orally with Leflunomide at a dose of 10, 30 or 70mg/kg/day from day 6 to 15 of pregnancy. At 70mg/kg, all embryos were resorbed and no live fetuses were detected. At 30mg/kg, Leflunomide reduced fetal viability, and increased the incidence of multiple external, skeletal and visceral malformations. Characteristic external malformations were neural tube defects, cleft palate and tail deformities. Limb malformations were observed in a small number of fetuses. Skeletal examinations revealed malformations of cervical to sacral vertebrae, ribs and sternebrae. In the viscerae, the main anomalies were membranous ventricular septum defect and persistent truncus arteriosus. The results of this study indicate that Leflunomide administered at 30mg/kg on days 6 to 15 of pregnancy can induce craniofacial malformations and deformities of the axial skeleton, heart and great vessels in mice.
Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Publishing Authors By Initials
Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Journal Published:
PUBLICATION TYPE: Journal Article
Journal: Reproductive toxicology (Elmsford, N.Y.)
VOLUME: 24
Page Numbers: 310-6
Journal Abbreviation: Reprod. Toxicol.
ISSN: 0890-6238
DAY: 18
MONTH: 05
YEAR: 2007
Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 8803591
Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice.
AFFILIATION: Drug Safety Evaluation, Developmental Research Laboratories, 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan.
Country: United States
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Reprod Toxicol
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice Related Publications